Based on proof-of-concept results from clinical trials at the UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.
Jonathan Serody, MD, the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology in the division of hematology and oncology, is part of the pre-clinical science team with Lineberger’s CAR-T program.
Learn more from Lineberger.